Orforglipron (Orforglipron (Oral Non-Peptide GLP-1 Agonist))
A first-in-class oral non-peptide GLP-1 receptor agonist with high oral bioavailability, potentially democratizing GLP-1 therapy without injections.
How it works
Small molecule agonist of GLP-1 receptors that mimics native GLP-1 binding without requiring peptide structure. Achieves full receptor activation with standard oral bioavailability.
Key facts
- Molecular weight: ~550 Da
- Half-life: 25-60 hours
- Bioavailability: Moderate-High (oral)
- Storage: Room temperature, protected from moisture.
Dosing overview
- Typical dose: 12-45 mg
- Frequency: Once daily
- Duration: Ongoing
- Route: Oral
Reported benefits
- Oral administration (no injection)
- No fasting requirement
- Significant weight loss (8-14%)
- Small molecule stability
- Lower manufacturing cost potential
Possible side effects
- Nausea (dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- Dyspepsia
Research
- Phase 2 trial of orforglipron for obesity (2023): Orforglipron 45mg produced 14.7% weight loss at 36 weeks with manageable GI side effects.
- Oral non-peptide GLP-1 agonist pharmacokinetics (2023): Consistent absorption without food restrictions, with 25-60 hour half-life supporting daily dosing.
Compare Orforglipron
Community discussions about Orforglipron
- Oral orforglipron first week – appetite shifts and mild nausea - 4 comments
- Thinking about Orforglipron for the convenience - 5 comments
- My first 6 weeks on oral Orforglipron – dose tweaks, nausea and step dip - 4 comments
- Orforglipron oral GLP-1 research looks interesting - 4 comments
- Orforglipron + low‑dose BPC‑157 for appetite and gut recovery – any thoughts? - 4 comments
- Ask the community about Orforglipron
Research and educational reference only. Not medical advice.